Loading…
Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes
Sulfonylureas are often titrated to maximum doses despite evidence that their efficacy plateaus above half-maximum doses. The aim of this study was to determine the impact of doubling the dose of glyburide and glipizide to high doses on hemoglobin A1c (HbA1c) in Veterans Affairs patients with type 2...
Saved in:
| Published in: | Acta diabetologica 2013-04, Vol.50 (2), p.261-265 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3 |
| container_end_page | 265 |
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Acta diabetologica |
| container_volume | 50 |
| creator | Hurren, Kathryn M. Bartley, Emily P. O’Neill, Jessica L. Ronis, David L. |
| description | Sulfonylureas are often titrated to maximum doses despite evidence that their efficacy plateaus above half-maximum doses. The aim of this study was to determine the impact of doubling the dose of glyburide and glipizide to high doses on hemoglobin A1c (HbA1c) in Veterans Affairs patients with type 2 diabetes. A retrospective review of 131 patient cases with prescriptions for high-dose glyburide or glipizide from July 1 through December 18, 2008, was conducted. Three dosage groups were examined: glyburide 5 mg twice daily increased to 10 mg twice daily (GLYB), glipizide 5 mg twice daily increased to 10 mg twice daily (GLIP
A
), and glipizide 10 mg twice daily increased to 20 mg twice daily (GLIP
B
). Each patient served as his or her own control; HbA1c after at least 75 days on each dose was compared. There was a statistically significant decrease in HbA1c in GLIP
A
only (mean ± SD 8.0 ± 1.0 vs. 7.6 ± 1.0%,
P
= 0.03). No significant change in HbA1c was detected in GLYB (8.1 ± 1.1 vs. 8.1 ± 1.3%,
P
= 0.80) and the evaluation of GLIP
B
(8.6 ± 1.7 vs. 8.2 ± 1.1%,
P
= 0.41) was not adequately powered due to the small sample size. In this small retrospective study, increasing glipizide, but not glyburide, from 5 mg to 10 mg twice daily significantly decreased HbA1c in patients with diabetes. |
| doi_str_mv | 10.1007/s00592-010-0197-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1346581248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1346581248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3</originalsourceid><addsrcrecordid>eNp1kcFq3EAMhofSkmy3eYBcwkAvvbgdaTy257iENA0Eeml7NWOPJvHi9WxHNmXfPrNsGkohIKGDPv0S-oW4BPUZlKq_sFLGYqFA5bR1AW_ECkqNhUGt34qVsqUqTIn2XLxn3ioFWOvmTJyjMoC60SuxvQmB-lnGIHkZQ5wO45LISR-ZJHHvRjcPcZI5HmkXH8bYDZPcQC9z-UUzJTex3ITghsRyn2GaZpZ_hvlRzoc9SZR-cF0G-YN4F9zIdPFc1-Ln15sf19-K---3d9eb-6LXNc5FqMEG4zwF06saidBo7b2ttPPOVUA1gsLQlL2pG-vBoEHlqNO-AgvQ6bX4dNLdp_h7IZ7b3cA9jaObKC7cgi4r0wCWTUY__odu45KmfN2RMray1hwpOFF9isyJQrtPw86lQwuqPRrRnoxosxHt0Yg8vBZXz8pLtyP_MvH38xnAE8C5NT1Q-mf1q6pP5dKSiQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1345969958</pqid></control><display><type>article</type><title>Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes</title><source>Springer Nature</source><creator>Hurren, Kathryn M. ; Bartley, Emily P. ; O’Neill, Jessica L. ; Ronis, David L.</creator><creatorcontrib>Hurren, Kathryn M. ; Bartley, Emily P. ; O’Neill, Jessica L. ; Ronis, David L.</creatorcontrib><description>Sulfonylureas are often titrated to maximum doses despite evidence that their efficacy plateaus above half-maximum doses. The aim of this study was to determine the impact of doubling the dose of glyburide and glipizide to high doses on hemoglobin A1c (HbA1c) in Veterans Affairs patients with type 2 diabetes. A retrospective review of 131 patient cases with prescriptions for high-dose glyburide or glipizide from July 1 through December 18, 2008, was conducted. Three dosage groups were examined: glyburide 5 mg twice daily increased to 10 mg twice daily (GLYB), glipizide 5 mg twice daily increased to 10 mg twice daily (GLIP
A
), and glipizide 10 mg twice daily increased to 20 mg twice daily (GLIP
B
). Each patient served as his or her own control; HbA1c after at least 75 days on each dose was compared. There was a statistically significant decrease in HbA1c in GLIP
A
only (mean ± SD 8.0 ± 1.0 vs. 7.6 ± 1.0%,
P
= 0.03). No significant change in HbA1c was detected in GLYB (8.1 ± 1.1 vs. 8.1 ± 1.3%,
P
= 0.80) and the evaluation of GLIP
B
(8.6 ± 1.7 vs. 8.2 ± 1.1%,
P
= 0.41) was not adequately powered due to the small sample size. In this small retrospective study, increasing glipizide, but not glyburide, from 5 mg to 10 mg twice daily significantly decreased HbA1c in patients with diabetes.</description><identifier>ISSN: 0940-5429</identifier><identifier>EISSN: 1432-5233</identifier><identifier>DOI: 10.1007/s00592-010-0197-1</identifier><identifier>PMID: 20512383</identifier><identifier>CODEN: ACDAEZ</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Aged ; Creatinine - blood ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Dose-Response Relationship, Drug ; Female ; Glipizide - administration & dosage ; Glyburide - administration & dosage ; Glycated Hemoglobin A - analysis ; Hemoglobin ; Humans ; Hypoglycemic Agents - administration & dosage ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Pharmacology ; Retrospective Studies ; Short Communication ; United States ; United States Department of Veterans Affairs ; Veterans</subject><ispartof>Acta diabetologica, 2013-04, Vol.50 (2), p.261-265</ispartof><rights>Springer-Verlag 2010</rights><rights>Springer-Verlag Italia 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3</citedby><cites>FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20512383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurren, Kathryn M.</creatorcontrib><creatorcontrib>Bartley, Emily P.</creatorcontrib><creatorcontrib>O’Neill, Jessica L.</creatorcontrib><creatorcontrib>Ronis, David L.</creatorcontrib><title>Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes</title><title>Acta diabetologica</title><addtitle>Acta Diabetol</addtitle><addtitle>Acta Diabetol</addtitle><description>Sulfonylureas are often titrated to maximum doses despite evidence that their efficacy plateaus above half-maximum doses. The aim of this study was to determine the impact of doubling the dose of glyburide and glipizide to high doses on hemoglobin A1c (HbA1c) in Veterans Affairs patients with type 2 diabetes. A retrospective review of 131 patient cases with prescriptions for high-dose glyburide or glipizide from July 1 through December 18, 2008, was conducted. Three dosage groups were examined: glyburide 5 mg twice daily increased to 10 mg twice daily (GLYB), glipizide 5 mg twice daily increased to 10 mg twice daily (GLIP
A
), and glipizide 10 mg twice daily increased to 20 mg twice daily (GLIP
B
). Each patient served as his or her own control; HbA1c after at least 75 days on each dose was compared. There was a statistically significant decrease in HbA1c in GLIP
A
only (mean ± SD 8.0 ± 1.0 vs. 7.6 ± 1.0%,
P
= 0.03). No significant change in HbA1c was detected in GLYB (8.1 ± 1.1 vs. 8.1 ± 1.3%,
P
= 0.80) and the evaluation of GLIP
B
(8.6 ± 1.7 vs. 8.2 ± 1.1%,
P
= 0.41) was not adequately powered due to the small sample size. In this small retrospective study, increasing glipizide, but not glyburide, from 5 mg to 10 mg twice daily significantly decreased HbA1c in patients with diabetes.</description><subject>Aged</subject><subject>Creatinine - blood</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Glipizide - administration & dosage</subject><subject>Glyburide - administration & dosage</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Pharmacology</subject><subject>Retrospective Studies</subject><subject>Short Communication</subject><subject>United States</subject><subject>United States Department of Veterans Affairs</subject><subject>Veterans</subject><issn>0940-5429</issn><issn>1432-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kcFq3EAMhofSkmy3eYBcwkAvvbgdaTy257iENA0Eeml7NWOPJvHi9WxHNmXfPrNsGkohIKGDPv0S-oW4BPUZlKq_sFLGYqFA5bR1AW_ECkqNhUGt34qVsqUqTIn2XLxn3ioFWOvmTJyjMoC60SuxvQmB-lnGIHkZQ5wO45LISR-ZJHHvRjcPcZI5HmkXH8bYDZPcQC9z-UUzJTex3ITghsRyn2GaZpZ_hvlRzoc9SZR-cF0G-YN4F9zIdPFc1-Ln15sf19-K---3d9eb-6LXNc5FqMEG4zwF06saidBo7b2ttPPOVUA1gsLQlL2pG-vBoEHlqNO-AgvQ6bX4dNLdp_h7IZ7b3cA9jaObKC7cgi4r0wCWTUY__odu45KmfN2RMray1hwpOFF9isyJQrtPw86lQwuqPRrRnoxosxHt0Yg8vBZXz8pLtyP_MvH38xnAE8C5NT1Q-mf1q6pP5dKSiQ</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Hurren, Kathryn M.</creator><creator>Bartley, Emily P.</creator><creator>O’Neill, Jessica L.</creator><creator>Ronis, David L.</creator><general>Springer Milan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130401</creationdate><title>Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes</title><author>Hurren, Kathryn M. ; Bartley, Emily P. ; O’Neill, Jessica L. ; Ronis, David L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Creatinine - blood</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Glipizide - administration & dosage</topic><topic>Glyburide - administration & dosage</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Pharmacology</topic><topic>Retrospective Studies</topic><topic>Short Communication</topic><topic>United States</topic><topic>United States Department of Veterans Affairs</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurren, Kathryn M.</creatorcontrib><creatorcontrib>Bartley, Emily P.</creatorcontrib><creatorcontrib>O’Neill, Jessica L.</creatorcontrib><creatorcontrib>Ronis, David L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Proquest Health and Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Acta diabetologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurren, Kathryn M.</au><au>Bartley, Emily P.</au><au>O’Neill, Jessica L.</au><au>Ronis, David L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes</atitle><jtitle>Acta diabetologica</jtitle><stitle>Acta Diabetol</stitle><addtitle>Acta Diabetol</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>50</volume><issue>2</issue><spage>261</spage><epage>265</epage><pages>261-265</pages><issn>0940-5429</issn><eissn>1432-5233</eissn><coden>ACDAEZ</coden><abstract>Sulfonylureas are often titrated to maximum doses despite evidence that their efficacy plateaus above half-maximum doses. The aim of this study was to determine the impact of doubling the dose of glyburide and glipizide to high doses on hemoglobin A1c (HbA1c) in Veterans Affairs patients with type 2 diabetes. A retrospective review of 131 patient cases with prescriptions for high-dose glyburide or glipizide from July 1 through December 18, 2008, was conducted. Three dosage groups were examined: glyburide 5 mg twice daily increased to 10 mg twice daily (GLYB), glipizide 5 mg twice daily increased to 10 mg twice daily (GLIP
A
), and glipizide 10 mg twice daily increased to 20 mg twice daily (GLIP
B
). Each patient served as his or her own control; HbA1c after at least 75 days on each dose was compared. There was a statistically significant decrease in HbA1c in GLIP
A
only (mean ± SD 8.0 ± 1.0 vs. 7.6 ± 1.0%,
P
= 0.03). No significant change in HbA1c was detected in GLYB (8.1 ± 1.1 vs. 8.1 ± 1.3%,
P
= 0.80) and the evaluation of GLIP
B
(8.6 ± 1.7 vs. 8.2 ± 1.1%,
P
= 0.41) was not adequately powered due to the small sample size. In this small retrospective study, increasing glipizide, but not glyburide, from 5 mg to 10 mg twice daily significantly decreased HbA1c in patients with diabetes.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>20512383</pmid><doi>10.1007/s00592-010-0197-1</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0940-5429 |
| ispartof | Acta diabetologica, 2013-04, Vol.50 (2), p.261-265 |
| issn | 0940-5429 1432-5233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1346581248 |
| source | Springer Nature |
| subjects | Aged Creatinine - blood Diabetes Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Female Glipizide - administration & dosage Glyburide - administration & dosage Glycated Hemoglobin A - analysis Hemoglobin Humans Hypoglycemic Agents - administration & dosage Internal Medicine Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Pharmacology Retrospective Studies Short Communication United States United States Department of Veterans Affairs Veterans |
| title | Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A11%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20sulfonylurea%20dose%20escalation%20on%20hemoglobin%20A1c%20in%20Veterans%20Affairs%20patients%20with%20type%202%20diabetes&rft.jtitle=Acta%20diabetologica&rft.au=Hurren,%20Kathryn%20M.&rft.date=2013-04-01&rft.volume=50&rft.issue=2&rft.spage=261&rft.epage=265&rft.pages=261-265&rft.issn=0940-5429&rft.eissn=1432-5233&rft.coden=ACDAEZ&rft_id=info:doi/10.1007/s00592-010-0197-1&rft_dat=%3Cproquest_cross%3E1346581248%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-f719f5adef5c072ee2533dd963adaa61e72102f84c5789d152520aeb3d61911b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1345969958&rft_id=info:pmid/20512383&rfr_iscdi=true |